NovelMed Therapeutics has reported positive interim data from a Phase I clinical trial of its complement blocker humanised monoclonal anti-Bb antibody, NM8074. 

NM8074 only attaches to disease-specific Bb and not to Factor B of the alternative pathway (AP), which gives a significant advantage over various other complement inhibitors. 

The first-in-human, randomised, double-blind, placebo-controlled, single ascending dose trial analysed the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity (ADA) of NM8074 in healthy subjects.

In the trial, 40 healthy subjects were given a single dose of NM8074 ranging from 0.3mg/kg to 20mg/kg. 

According to the interim results, NM8074 was found to be safe at all analysed doses and was well tolerated. 

On testing classical pathway (CP) and alternative pathway (AP) function using assays, NM8074 was demonstrated to be specific to the AP and did not impact CP, which is vital for host defence. 

These findings also validate the data from in vitro studies carried out by the company analysing the sera from healthy participants and patients with paroxysmal nocturnal hemoglobinuria (PNH). 

Furthermore, NM8074 was found to possess targeted specificity for the AP while leaving CP in in vitro studies.

Further trials in PNH are being readied as the full assessment of all dose arms for concluding the Phase I trial is progressing.

The initial data marks the first clinical milestone for developing NM8074 as a safe treatment for complement-mediated inflammation and hemolysis linked with PNH, as well as various other complement disorders.

NovelMed CEO Rekha Bansal said: “This is the first study to demonstrate that selective blockade of Bb can be safely achieved in a clinical study.

“We believe that NM8074 would address the deficiencies associated with current treatments, both approved or in development.”